Anthera Pharmaceuticals, Inc.
ANTH
$0.00
$0.000.00%
OTC PK
| 03/31/2018 | 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Cost of Revenue | -36.25% | -38.39% | -26.12% | 2.33% | 28.53% |
| Gross Profit | 36.25% | 38.20% | 22.38% | -10.28% | -41.15% |
| SG&A Expenses | -27.25% | -28.30% | 9.78% | 22.85% | 48.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.36% | -36.44% | -19.78% | 6.12% | 32.26% |
| Operating Income | 34.36% | 36.28% | 16.47% | -12.75% | -42.65% |
| Income Before Tax | 57.47% | 51.60% | 39.48% | 9.77% | -40.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.47% | 51.60% | 39.48% | 9.77% | -40.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.47% | 51.60% | 39.48% | 9.77% | -40.01% |
| EBIT | 34.36% | 36.28% | 16.47% | -12.75% | -42.65% |
| EBITDA | 34.79% | 36.48% | 16.49% | -12.76% | -43.09% |
| EPS Basic | 86.45% | 74.23% | 52.73% | -8.73% | -54.41% |
| Normalized Basic EPS | 83.69% | 73.50% | 53.31% | 19.83% | -23.01% |
| EPS Diluted | 86.45% | 74.23% | 52.73% | -8.73% | -54.41% |
| Normalized Diluted EPS | 83.69% | 73.50% | 53.31% | 19.83% | -23.01% |
| Average Basic Shares Outstanding | 151.90% | 98.68% | 62.99% | 36.84% | 15.60% |
| Average Diluted Shares Outstanding | 151.90% | 98.68% | 62.99% | 36.84% | 15.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |